Welcome to our dedicated page for Ispecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on Ispecimen stock.
iSpecimen Inc. reports developments tied to its online marketplace for human biospecimens, which connects life science researchers with a network of healthcare specimen providers. Company updates cover biospecimen sourcing for research projects, supplier-network responsiveness, direct-to-customer shipping, and marketplace technology used to match customer requests with available inventory.
Recurring news themes include AI-assisted inventory matching, SalesStack marketplace integration, respiratory and other specimen procurement, international sourcing relationships, and capital-structure actions such as the completed reverse stock split of ISPC common stock.
iSpecimen (Nasdaq: ISPC) has enhanced its custom biofluids collection service to deliver urgently needed research samples faster to life sciences organizations. Originally developed during COVID-19, this service allows researchers, particularly in the Boston area, to receive direct blood draws and saliva samples within hours. CEO Christopher Ianelli emphasized that this service aims to meet ongoing demands for fresh specimens, thus supporting medical research effectively. Additionally, iSpecimen invites Boston-area individuals to donate biospecimens for research purposes.
iSpecimen Inc. (Nasdaq: ISPC) will report its financial results for the second quarter ending June 30, 2021, before market open on August 10, 2021. A conference call and audio webcast will take place at 8:30 a.m. Eastern Time the same day, featuring remarks from CEO Christopher Ianelli, CFO Tracy Curley, and COO Jill Mullan. Those unable to attend can access a replay until August 24, 2021. iSpecimen operates an online marketplace for human biospecimens, connecting researchers with healthcare providers.
On July 1, 2021, iSpecimen (Nasdaq: ISPC) announced the closing of an additional 337,500 shares of common stock due to the full exercise of the underwriters' over-allotment option in its initial public offering (IPO). The shares were sold at $8.00 each, raising $2.7 million and increasing the total gross proceeds of the IPO to $20.7 million. iSpecimen's shares began trading on June 17, 2021. ThinkEquity managed the IPO, and a registration statement was effective as of June 16, 2021.
iSpecimen has successfully closed its initial public offering (IPO) of 2,250,000 shares at $8.00 per share, generating $18 million in gross proceeds. The shares began trading on the Nasdaq Capital Market under the ticker ISPC on June 17, 2021. This offering was managed by ThinkEquity, a division of Fordham Financial Management. The funds raised will support the company's online marketplace connecting life scientists with healthcare providers for biospecimens, enhancing medical discovery capabilities.
iSpecimen, an online marketplace for human biospecimens, announced the pricing of its initial public offering (IPO) of 2,250,000 shares at $8.00 per share, raising $18 million before expenses. The offering includes a 45-day option for underwriters to buy an additional 337,500 shares. Trading is set to begin on the Nasdaq under the symbol 'ISPC' on June 17, 2021, with the offering expected to close on June 21, 2021. Proceeds will fund technology development, marketing, and debt repayment.